When the FDA demands a new standard of balance in how benefits and risks are communicated, it should be framed against the larger backdrop of what harms Americans every day.

Working with agency partner DCX Growth Accelerator, GeneDX takes direct aim at the issue of underdiagnosis of pediatric rare diseases.

Today, although only a small subset of HCPs uses social primarily for creation, those who do have significant sway. Sixty-six percent of consumers interact with HCP influencers — more than relevant ...

The Trump administration is continuing its push to revise federal guidelines to delay the hepatitis B vaccine newborn dose for most children.

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions ...

Even if people qualify for financial help with their hospital bills, the care they receive may not be covered.

The 100% pharma tariff threat; Drugmakers make moves ahead of MFN deadline; RFK Jr. mulls adding autism symptoms to vaccine injury program.

Legal and regulatory experts expect litigation to arise if the FDA seeks to enforce its pharma DTC ad crackdown, though how it might play out is nuanced.

The FDA asserted that the 90-second TV ad misbrands Novartis’ Fabhalta and makes the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.

More and more patients are turning to AI for therapy, but the space is becoming littered with negative outcomes. Can marketers change this trajectory?

Clinical teams across the country are forming a five-year, $37 million consortium to research stillbirth, a long-neglected public health concern. “There’s no question that the ProPublica reporting was ...

The hospital said the price for Deborah Buttgereit’s surgery increased because doctors encountered complications midprocedure.